Icon
+91 94997 68112
Login Register

Invanz - (1 g/vial; Injectable, Intramuscular, Intravenous)

Ertapenem Merck
1 g/vial; Injectable, Intramuscular, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
Less Than 5
Less Than 5
Indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis caused by bacteria
Yes
****** *** *** ***** ** **** **** ** **** ****** '*** (*** **, ****) *** *** *********. ** ** ********* ** **** **** ****** *** *** ********* ****** *** ********** ** ****, ******* *** ********** **** ****** *** ********* ***** *** ***** ** ********* *** *** ***** *** ** ****** ** ** ** **** **** ****** *** ****. ***** ******* ***** **** ** **** **** ****** *** *** *********. ******* * ****** ******* ****** ****** ******* **** ***** **** ** **** ******* '*** (*** ** ******- ****** ** *** **, ****), '*** (*** **, ****), '*** (*** ** ******- ****** ** ***** **, ****) *** *** ************ *********. *** ********** **** ******* *** ****** ******* **** ********* ***** ** ******* *** ** ******** ****. ***** **** ***** ********* *** & ********* **** ***** ****. ********* ** *****'* ****** *** ****** ***** ******* ****** ********** **** *** ****. *****, ** **** **** ******* *** ** ***** **** *** ****** ** ******* '*** *** '*** *** *******. *** **'* ******** *** ****** ** *** ******* *******. **** ** *** ********* **** ******** ********* ******** **** ****.
Invanz Patent 1 Patent 2 Patent 3
****** ******* ******* *******
******* *** ******* ******* *******
****** ******* ******* (*** ** **) ******* (*** ** **) *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* **** ****** **** ********
****** ******* ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
******* *** ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
  1. *** **, **** : ****** ******** ***** ***** *** **** ** *** ***** **** ****** '*** (*** **, ****).
  2. *** **, **** : ***** ***** * **** ******* ****** ** ******** ***** ** ********.
  3. *** **, **** : ******* ******** ***** ***** *** **** ** **** ****** '*** (*** **, ****).
  4. *** **, **** : ***** ***** **** ******* ****** ******* **** ** *** ******* ***** **** ** **** ******* '*** (*** ** ******- ****** ** *** **, ****), '*** (*** **, ****), '*** (*** ** ******- ****** ** ***** **, ****).
  5. *** **, **** : ********** *** ********* **** ****** ***** *** ***** ** ********* *** *** *****.
  6. *** **, **** : **** ******* ******* *** ****** **** ******** ** ***** ** *******.
  7. *** **, **** : ***** ******** *** ******** ** ******* *******.
  8. *** *, **** : ***** **** ******* *** ************ ** ******* (*** **, ****), ******* & *******.
  9. *** **, **** : ** ***** ** ***** ** ******* *** **** **** ****** ** ******* *** ******* *** *******.
  10. *** **, **** : ******* ******* ****** ** ******** ** *********** ** ******* ****** ** **** ******* *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.